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Figure 1. Multivariate analysis of mortality
Conclusion: Patients with RDs had higher comorbidities, hospitalizations, and 
mortality than the general population in the bivariate analysis. However, adjusted 
multivariate analysis showed that the odds for mortality were not increased 
because of having a RD. These findings suggest that the increased mortality of 
Mexican patients with RDs may be explained by the higher frequency of comor-
bidities in this population.
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Background: SARS-CoV-2 infection poses a serious challenge for patients 
with rheumatic autoimmune systemic diseases (ASD), characterized by marked 
immune-system dysregulation and frequent visceral organ involvement.
Objectives: To evaluate the impact of Covid-19 pandemic in a large series of 
Italian patients with ASD.
Methods: Our multicenter telephone survey (8-week period, March-April 2020) 
included a large series of 2,994 patients (584 M, 2,410 F, mean age 58.9±13.4SD 
years) with ASD followed at 34 tertiary referral centers of 14 regions of northern, 
central, and southern Italian macro areas, characterized by different prevalence 
of SARS-CoV-2 infection. According to currently used criteria, Covid-19 was clas-
sified as definite Covid-19 (signs or symptoms of Covid-19 confirmed by positive 
oral/nasopharyngeal swabs at PCR testing) or highly suspected Covid-19 (signs 
or symptoms highly suggestive of Covid-19, but not confirmed by PCR testing 
due to limited availability of virological tests in that period). The results were ana-
lyzed performing the Odds Ratio by Java-Stat 2-way Contingency Table Analysis.
Results: The main findings of the survey study revealed a significantly increased 
prevalence of Covid-19 in:
a.the whole series of ASD patients (definite Covid-19: 22/2994, 0.73%; p=0.0007;
definite Covid-19 plus highly suspected Covid-19: 74/2,994, 2.47%; p<0.0001) 
when compared to Italian general population of Covid-19 infected individuals 
(349/100000 = 0.34%; data from Italian Superior Institute of Health;
h t t p s : / / w w w . e p i c e n t r o . i s s . i t / e n / c o r o n a v i r u s /
sars-cov-2-national-surveillance-system).
b.the subgroup of patients with connective tissue diseases or systemic vas-
culitis (n = 1,901) compared to the subgroup of inflammatory arthritis (n = 
1,093), namely rheumatoid arthritis, psoriatic arthritis, ankylosing spondyli-
tis (definite Covid-19: 19/1,901, 0.99%, vs 3/1,093, 0.27%; p=0.036; definite 
Covid-19 plus highly suspected Covid-19: 69/1,901, 3.6%, vs 5/1,093, 0.45%; 
p<0.0001)
c.the subgroup of patients with pre-existing interstitial lung involvement (n = 526) 
compared to those without (n = 2,468) (definite Covid-19: 10/526, 1.90%, vs 
12/2,468, 0.48%; p=0.0015; definite Covid-19 plus highly suspected Covid-19: 
33/526, 6.27%, vs 41/2,468, 1.66%; p<0.0001).
Table 1. Comparison of patients with COVID-19 with and without RDs
 COVID-19 patients 
without RDs




N 969 323  
Age (mean (SD)) 42.6 (17.4) 51.2 (13.9) <0.001
Sex = Male (%) 455 (47.0) 55 (17.0) <0.001
Deceased = Yes (%) 55 (5.7) 43 (13.3) <0.001
Hospitalization = Hospitalized 
(%)
164 (16.9) 152 (47.1) <0.001
Intubation = Yes (%) 27 (2.8) 32 (11.8) <0.001
COPD_Asthma = Yes (%) 37 (3.8) 15 (4.6) 0.522
Diabetes = Yes (%) 114 (11.8) 49 (15.2) 0.116
Obesity = Yes (%) 128 (13.3) 21 (6.5) 0.001
Hypertension = Yes (%) 152 (15.8) 88 (27.2) <0.001
Cardiovascular disease = Yes 
(%)
19 (2.0) 14 (4.3) 0.02
CRF = Yes (%) 22 (2.3) 17 (5.3) 0.007
Pregnancy = Yes (%) 5 (0.5) 2 (0.6) 0.827
Smoker = Yes (%) 86 (8.9) 10 (3.1) 0.001













is: first published as 10.1136/annrheum





Scientific Abstracts  907
Of interest, the prevalence of Covid-19 did not correlate with presence/absence 
of different comorbidities, mainly diabetes, cardio-vascular and/or renal disor-
ders, as well as of ongoing treatments with biological DMARDs; while patients 
treated with conventional DMARDs showed a significantly lower prevalence of 
Covid-19 compared to those without. Covid-19 was more frequently observed in 
the patients’ populations from northern and central compared to southern Italian 
macro area with lower diffusion of pandemic. Clinical manifestations of Covid-19, 
observed in 74 patients, were generally mild or moderate; 4/9 individuals requir-
ing hospital admission died for severe pneumonia.
Conclusion: The prevalence of Covid-19 observed in ASD patients during the 
first wave of pandemic was significantly higher than that observed in Italian gen-
eral population; moreover, the actual prevalence of Covid-19 might be underes-
timated due to the high number of mild variants as well as the possible clinical 
overlapping between these two conditions. Patients with ASD should be invaria-
bly regarded as ‘frail patients’ during the pandemic course, considering the risk of 
worse outcome in the acute phase of Covid-19, as well as the potential long-term 
effects of viral infection.
The statistically significant association of Covid-19 with connective tissue dis-
eases/systemic vasculitis, as well as with pre-existing interstitial lung involvement, 
suggests the presence of distinct clinico-pathological ASD subsets, character-
ized by markedly different patients’ vulnerability to SARS-CoV-2 infection.
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Background: Coronavirus disease 2019 (COVID-19) is a pandemic-spread sys-
temic infectious disease with prominent respiratory manifestations and signif-
icant associated morbidity and mortality. Elderly people are most significantly 
affected with mortality ranging from 2.4% (age 60-69) to 19.6% (age>80) in Euro-
pean Countries. The prevalence of COVID-19 and of its complications in patients 
with immune-mediated disorders, remains unclear. The frequency and impact of 
COVID-19 on patients with IgG4-related diease (IgG4-RD), many of whom are 
on concurrent immunosuppression has not been addressed.
Objectives: To assess the epidemiological and clinical relevance of COVID-19 
in patients with IgG4-RD.
Methods: This is a multi-centre retrospective observational study of IgG4-RD 
patients from France, Italy, Spain and the United Kingdom. Demographics, 
comorbidities, IgG4-RD features, current and past treatment along with COV-
ID-19-suggestive symptoms and COVID-19 diagnoses from February 2020 to 
January 2021 were recorded by means of direct or phone interviews. Patients 
with reverse-transcriptase polymerase chain reaction-confirmed (cCOVID) or 
presumed COVID-19 based on clinical, serological or imaging features (pCOVID) 
were pooled for analysis (totCOVID) and compared to patients who were not 
diagnosed with COVID-19. Inter-group comparison of categorical and quantita-
tive variables were performed by using the chi-square test with Fisher’s correc-
tion and the Mann-Whitney’s test respectively. Data are expressed as median 
(interquartile range) unless otherwise specified.
Results: A total of 305 patients [71% males, median age 64 (54-74) years] were 
studied. Pancreato-biliary disease was the most frequently observed IgG4-RD 
phenotype (39%). Fifty-one percent of patients were taking corticosteroids at 
time of interview and 30% were on biological or conventional immunosuppres-
sants. Thirty-two totCOVID cases (23 cCOVID, nine pCOVID) were identified: 
11/32 were hospitalised, two needed intensive care and four (13%; 3/4 aged >80 
years) died. Having one or more infected family members was a risk factor for 
COVID-19 in patients with IgG4-RD (OR=19.9; p<0.001). No other demographic, 
clinical or treatment features associated with COVID-19. In particular there was 
no association between adverse outcomes with COVID-19 and higher doses of 
steroids (>20mg) or rituximab administration.
Conclusion: The prevalence and course of COVID-19 in IgG4-RD patients are 
similar to those of the general population of the same age, with no evident impact 
of disease- or treatment-related factors to the basal infectious risk. Effective pub-
lic health countermeasures might be beneficial for patients with IgG4RD.
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Background: Efficacious vaccines are urgently needed to contain the ongoing 
coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). On December 11, 2020, the 
Food and Drug Administration (FDA) issued an Emergency Use Authorization 
(EUA) for Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19, administered 
as 2 doses separated by 21 days (1)
On December 27, 2020, Italy started use of Pfizer-BioNTech COVID-19 vaccine 
and initial doses were reserved for health care personnel
Objectives: The primary end points were the safety of each administered dose 
in patients with Rheumatic diseases (RD’s)
Methods: In this multicenter, observational study, we interviewed by phone 27 
patients with rheumatic diseases (RDs) and 30 healthy subjects receiving the 
Pfizer-BioNTech vaccine (0.3 ml i.m. in two doses 21 days apart, time 0 and 3 
weeks).
Results: As of 30 January 2021, 57 subjects (27 patients and 30 healthy sub-
jects) were interviewed. The epidemiological and clinical features of the 27 
patients are reported in Table 1. Among the whole population, 35 subjects (16 
patients and 19 healthy subjects) complained of an adverse event after the first 
vaccine dose, with symptom onset occurring within 1 day of vaccination. All 
adverse events (100%) were classified as nonserious and included: injection site 
pain (17), fatigue (5), headache (16), fever (3), tachycardia (2), and paresthesia 
(2).
After 21 days, 6 patients and 11 healthy subjects received the second vac-
cine dose. Fifteen (5 patients and 10 healthy subjects) of them (88%) reported 
adverse events, again categorized as nonserious. Specifically, injection site pain 
(7), fatigue (10), headache (10), fever (10), paresthesia (1), cutaneous vasculitis 
(1), itchy and scratchy throat (1), diarrhea (4), lymph node enlargement (1) were 
recorded. No differences were noted between patients with RDs and healthy 
subjects in terms of adverse events.
Conclusion: This preliminary study shows that the Pfizer-BioNTech COVID-19 
vaccine is as safe in patients with RDs as in healthy subjects. Whether patients 
with RDs will develop protective titers of anti-SARS-CoV-2 antibodies as com-
pared to healthy subjects will be evaluated in further, ongoing studies.
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